92 related articles for article (PubMed ID: 9028558)
1. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
Messori A; Bonistalli L; Costantini M; Alterini R
Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
[TBL] [Abstract][Full Text] [Related]
3. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
Beard SM; Lorigan PC; Sampson FC
Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
[TBL] [Abstract][Full Text] [Related]
5. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
[TBL] [Abstract][Full Text] [Related]
6. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting.
Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
Intern Med J; 2009 Aug; 39(8):519-26. PubMed ID: 19732200
[TBL] [Abstract][Full Text] [Related]
7. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo.
Messori A; Bosi A; Bacci S; Laszlo D; Trippoli S; Locatelli F; Van Lint MT; Di Bartolomeo P; Amici A
Bone Marrow Transplant; 1999 Mar; 23(5):489-95. PubMed ID: 10100564
[TBL] [Abstract][Full Text] [Related]
8. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
11. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
13. [Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia].
Uyl-de Groot CA; Rutten FF
Ned Tijdschr Geneeskd; 1994 Jan; 138(1):28-31. PubMed ID: 8289955
[TBL] [Abstract][Full Text] [Related]
14. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
[TBL] [Abstract][Full Text] [Related]
15. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
16. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
Bolwell B; Goormastic M; Andresen S
Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
Hillner BE; Smith TJ; Desch CE
JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
19. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
[TBL] [Abstract][Full Text] [Related]
20. The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant.
Schimmer AD; Dranitsaris G; Ali V; Falconer M; Keating A
Support Care Cancer; 2002 Apr; 10(3):247-52. PubMed ID: 11904790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
